The 10/11 PR is chock full of goodies. It's deserving of multiple reads to take it all in. I think D. Gold wrote it. He's an excellent writer. The 10/10 PR had a different author. It's rambling and badly composed except for the last section about Dharmarol that was probably written by Gold. I had to edit the 10/10 PR so I could read it through without gagging. lol
October 10, 2013 15:30 ET
SKTO's Medical Greens Announces Licensing Agreement for Revolutionary New High Dose MMJ Delivery Option Dharmanol™
LOS ANGELES, CA--(Marketwired - Oct 10, 2013) - SK3 Group, Inc.'s (OTC Pink: SKTO) subsidiary, Medical Greens, is pleased to announce that it has obtained the exclusive license for Dharmanol™ for the State of California. Dr. Charles Apel of Berkeley Bio-Organic Research Laboratories has developed a proprietary technology to extract, stabilize, and preserve the medicinal cannabinoids found in hemp and marijuana in their non-psychoactive form. This technology allows patients to consume cannabinoid medicine without any of the "high" or "stoned" effects.
"We consider this to be a major breakthrough in the treatment of cancer using cannabinoids. The results seen by those groups and individuals promoting the use of what has been dubbed 'Simpson' therapy have been very convincing. The problem, however, has been that many people who are fighting cancer, and have no experience with cannabis, cannot take the emotional and mental effects that come from following the regimen, which requires consumption of a gram of cannabis extract oil every day for several months. This is the equivalent of smoking up to 100 marijuana cigarettes every day. The "high" from the experience is truly overwhelming, and we have seen patients choose to discontinue the therapy, even though doing so likely leads to negative effects on their treatment," said D. Gold, Dr. Apel's partner in development of the process. "Now patients will be able to consume the large doses necessary for this therapy to be effective, with none of the psychoactive side effects that have been such an unforgiving part of the therapy."
Dharmanol™ (pronounced DAR-mah-nol) will be available in two forms: low-dose non-psychoactive tablets and high-doses. The low-dose non-psychoactive tablets can be taken daily as a nutritional supplement to stimulate the endo-cannabinoid system, an internal system which controls and regulates many other bodily systems such as immune response. Much research has shown that there is substantial medicinal benefit in "stimulating" a compromised endo-cannabinoid system with cannabinoids, causing the other systems to work as they should.
These tablets will contain an array of the most beneficial non-psychoactive cannabinoids. Each tablet will contain 5 mg. of CBD, 5 mg. of mixed cannabinoids in their non-psychoactive form (known as mixed carboxylates) and 5 mg. of a steam-distilled mixture of the natural terpenes and terpenoids found in cannabis and hemp. The terpene element is thought to be responsible for the increased medicinal efficacy of "whole plant" cannabis preparations.
At the opposite end of the spectrum is using high dosage Dharmanol™ much like the "Simpson" therapy. High doses can be taken daily with no psychoactive effects. On observing the positive results that patients are receiving with standard Simpson therapy, most people studying cannabis medicine agree that if the dose could be increased ten or a hundred times, its already substantial efficacy against cancer will be similarly enhanced. Now this is possible thanks to the removal of the "high" from the cannabinoids in the production of Dharmanol™.
"We believe that we have crossed the bridge, so to speak, between the incredible medicinal efficacy of the cannabis plant and the world of nutraceutical supplements. Now people will be able to benefit from the substantial health-giving aspects of the cannabis plant, without the 'high' and related side effects that have kept this wonderful herb from entering the world of mainstream medicine. Dr. Apel and I would like to thank all those who have worked so hard on this project to help us develop this new technology," said Gold.
"We are pleased to have acquired this exclusive license to this important new product in the fight against disease using medical cannabis," said Artemus Mayor, President of SK3 Group. "We expect it to be in high demand with collectives and consumers."
Dharmanol™ tablets will be distributed through the collectives managed by or partnered with Medical Greens, which currently has products in over 75 collectives in the state of California. The Manufacturer's Suggested Retail Price will be $25.00 per bottle for 8 capsules.
About SK3
SK3 is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 brings standardization and transparency to this rapidly growing segment of the alternative care field.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
FDA Disclaimer
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent disease. Use only as directed.
ORIGINAL
Oct. 11, 2013, 3:18 p.m. EDT
SKTO Announces Third Quarter Report Date and Conference Call and Milestones
LOS ANGELES, CA, Oct 11, 2013 (Marketwired via COMTEX) -- SK3 Group, Inc. (otc pink:SKTO) ("the Company") announced that it plans to release 3rd quarter results by month's end.
As part of the Company's effort to enhance its operations, management is improving its reporting efforts and as a result will issue the 3rd quarter results early. "We are continuing to bolster our managerial services and as a result we will be better able to report to our shareholders results of operations for the 3rd quarter and 9 months ending September 30, 2013, earlier than required," stated Mr. Artemus Mayor, President of SK3 Group, Inc. "We will also post to our web-site a pre-recorded conference call with the officers of the Company shortly after the reporting of our 3rd quarter fiscal results," Mr. Mayor added. "While we had said before we may do a management conference call earlier in the month, we think it prudent to wait until after we have released the financials so that management can better respond to that information and any investor questions relating thereto."
For the near term, the Company's milestones include increasing revenues, steadily collecting receivables, expanding product offerings, enhancing the team and its capabilities, and cleaning up various corporate issues such as the CUSIP, dividend, name change, audits, and other operational issues.
"The Company had a terrific third quarter and when the financial results are released investors will see that we have continued in our long term focus to collect receivables and enhance revenues, increase cash on hand while investing intelligently in the business, focus on personnel and acquiring the right business relationships, and otherwise expand the Company's role in the medical marijuana space," said Kevin Allyn, the Company's Chairman. "We are looking forward to sharing more details with our investors on each of these points in the near future. But investors will be able to measure our long term progress by how we fare against our milestones."
Previously the Company announced, that its wholly owned subsidiary Medical Greens announced that it has obtained the exclusive license for Dharmanol(TM) for the State of California. Dr. Charles Apel, of Berkeley Bio-Organic Research Laboratories has developed a proprietary technology to extract, stabilize, and preserve the medicinal cannabinoids found in hemp and marijuana in their non-psychoactive form. This technology allows patients to consume cannabinoid medicine without any of the "high" or "stoned" effects.
Dharmanol(TM) (pronounced DAR-mah-nol) will be available in two forms: low-dose non-psychoactive tablets and high-doses. The low-dose non-psychoactive tablets can be taken daily as a nutritional supplement to stimulate the endo-cannabinoid system, an internal system which controls and regulates many other bodily systems such as immune response. Much research has shown that there is substantial medicinal benefit in "stimulating" a compromised endo-cannabinoid system with cannabinoids, causing the other systems to work as they should.
The Company reserves the right to modify or amend its milestones at any time in response to business issues or for any other reason.
About SK3 Group, Inc. SK3 is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 brings standardization and transparency to this rapidly growing segment of the alternative care field.
Safe Harbor Statement Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes", "expects", "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. This news release speaks as of the date first set forth above and no responsibility or obligation may be assumed or exists to update the information included herein for events occurring after the date
FDA Disclaimer These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent disease. Use only as directed.
Edited version
SKTO Announces Third Quarter Report Date. Also Announces Conference Call and Company Milestones.
SK3 Group, Inc. (OTC Pink:SKTO) ("the Company") announced that it plans to release its Quarter III results by month's end.
"Having enhanced our operations and having bolstered our managerial services, the Company is able to report the results of its operations for Quarter III and for the 9 months ending 30 September 2013 earlier than required," said Artemus Mayor, president of SK3 Group, Inc.
"Shortly after reporting our Quarter III fiscal results, we will post on http://www.medicalgreens.com a pre-recorded conference call with the officers of the Company discussing the results and replying to investor questions," added Mr. Mayor.
According to Kevin Allyn, Chairman of SK3 Group, Inc., "The Company had a terrific third quarter."
Mr. Allyn continued, "When the financial results are released, investors will see that we continue in our long-term focus to collect receivables, enhance revenues, and increase cash on hand -- while investing intelligently in the business. We also continue to focus on personnel and acquiring the right business relationships, as we expand the Company's role in the medical marijuana space. We look forward to sharing more details with our investors on each of these points in the near future. Investors will be able to measure our long term progress by how we fare against our milestones."
For the near term, the Company's milestones include increasing revenues, steadily collecting receivables, expanding product offerings, and enhancing the team and its capabilities. Other milestones include cleaning up various corporate matters such as the Company name change, CUSIP change, dividend, audits, and other operational issues.
Previously, the Company announced that its wholly owned subsidiary Medical Greens has obtained the exclusive license for Dharmanol(TM) for the State of California. Dr. Charles Apel of Berkeley Bio-Organic Research Laboratories has developed a proprietary technology to extract, stabilize, and preserve the medicinal cannabinoids found in hemp and marijuana in their non-psychoactive form. This technology allows patients to consume cannabinoid medicine without any of the "high" or "stoned" effects.
Dharmanol(TM) (pronounced DAR-mah-nol) will be available in two forms: low-dose non-psychoactive tablets and high doses. The low-dose non-psychoactive tablets can be taken daily as a nutritional supplement to stimulate the endo-cannabinoid system, an internal system which controls and regulates many other bodily systems such as immune response. Much research has shown that there is substantial medicinal benefit in "stimulating" a compromised endo-cannabinoid system with cannabinoids, causing the other systems to work as they should.
The Company reserves the right to modify or amend its milestones at any time in response to business issues or for any other reason.
About SK3 Group, Inc. SK3 is a healthcare logistics and fulfillmentconsultancy focused on the delivery of alternative care and medicine.With seasoned management, breakthrough technology and best practices,SK3 brings standardization and transparency to this rapidly growingsegment of the alternative care field.
October 10, 2013 15:30 ET
SKTO's Medical Greens Announces Licensing Agreement for Revolutionary New High Dose MMJ Delivery Option Dharmanol™
LOS ANGELES, CA--(Marketwired - Oct 10, 2013) - SK3 Group, Inc.'s (OTC Pink: SKTO) subsidiary, Medical Greens, is pleased to announce that it has obtained the exclusive license for Dharmanol™ for the State of California. Dr. Charles Apel of Berkeley Bio-Organic Research Laboratories has developed a proprietary technology to extract, stabilize, and preserve the medicinal cannabinoids found in hemp and marijuana in their non-psychoactive form. This technology allows patients to consume cannabinoid medicine without any of the "high" or "stoned" effects.
"We consider this to be a major breakthrough in the treatment of cancer using cannabinoids. The results seen by those groups and individuals promoting the use of what has been dubbed 'Simpson' therapy have been very convincing. The problem, however, has been that many people who are fighting cancer, and have no experience with cannabis, cannot take the emotional and mental effects that come from following the regimen, which requires consumption of a gram of cannabis extract oil every day for several months. This is the equivalent of smoking up to 100 marijuana cigarettes every day. The "high" from the experience is truly overwhelming, and we have seen patients choose to discontinue the therapy, even though doing so likely leads to negative effects on their treatment," said D. Gold, Dr. Apel's partner in development of the process. "Now patients will be able to consume the large doses necessary for this therapy to be effective, with none of the psychoactive side effects that have been such an unforgiving part of the therapy."
Dharmanol™ (pronounced DAR-mah-nol) will be available in two forms: low-dose non-psychoactive tablets and high-doses. The low-dose non-psychoactive tablets can be taken daily as a nutritional supplement to stimulate the endo-cannabinoid system, an internal system which controls and regulates many other bodily systems such as immune response. Much research has shown that there is substantial medicinal benefit in "stimulating" a compromised endo-cannabinoid system with cannabinoids, causing the other systems to work as they should.
These tablets will contain an array of the most beneficial non-psychoactive cannabinoids. Each tablet will contain 5 mg. of CBD, 5 mg. of mixed cannabinoids in their non-psychoactive form (known as mixed carboxylates) and 5 mg. of a steam-distilled mixture of the natural terpenes and terpenoids found in cannabis and hemp. The terpene element is thought to be responsible for the increased medicinal efficacy of "whole plant" cannabis preparations.
At the opposite end of the spectrum is using high dosage Dharmanol™ much like the "Simpson" therapy. High doses can be taken daily with no psychoactive effects. On observing the positive results that patients are receiving with standard Simpson therapy, most people studying cannabis medicine agree that if the dose could be increased ten or a hundred times, its already substantial efficacy against cancer will be similarly enhanced. Now this is possible thanks to the removal of the "high" from the cannabinoids in the production of Dharmanol™.
"We believe that we have crossed the bridge, so to speak, between the incredible medicinal efficacy of the cannabis plant and the world of nutraceutical supplements. Now people will be able to benefit from the substantial health-giving aspects of the cannabis plant, without the 'high' and related side effects that have kept this wonderful herb from entering the world of mainstream medicine. Dr. Apel and I would like to thank all those who have worked so hard on this project to help us develop this new technology," said Gold.
"We are pleased to have acquired this exclusive license to this important new product in the fight against disease using medical cannabis," said Artemus Mayor, President of SK3 Group. "We expect it to be in high demand with collectives and consumers."
Dharmanol™ tablets will be distributed through the collectives managed by or partnered with Medical Greens, which currently has products in over 75 collectives in the state of California. The Manufacturer's Suggested Retail Price will be $25.00 per bottle for 8 capsules.
About SK3
SK3 is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 brings standardization and transparency to this rapidly growing segment of the alternative care field.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
FDA Disclaimer
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent disease. Use only as directed.
ORIGINAL
Oct. 11, 2013, 3:18 p.m. EDT
SKTO Announces Third Quarter Report Date and Conference Call and Milestones
LOS ANGELES, CA, Oct 11, 2013 (Marketwired via COMTEX) -- SK3 Group, Inc. (otc pink:SKTO) ("the Company") announced that it plans to release 3rd quarter results by month's end.
As part of the Company's effort to enhance its operations, management is improving its reporting efforts and as a result will issue the 3rd quarter results early. "We are continuing to bolster our managerial services and as a result we will be better able to report to our shareholders results of operations for the 3rd quarter and 9 months ending September 30, 2013, earlier than required," stated Mr. Artemus Mayor, President of SK3 Group, Inc. "We will also post to our web-site a pre-recorded conference call with the officers of the Company shortly after the reporting of our 3rd quarter fiscal results," Mr. Mayor added. "While we had said before we may do a management conference call earlier in the month, we think it prudent to wait until after we have released the financials so that management can better respond to that information and any investor questions relating thereto."
For the near term, the Company's milestones include increasing revenues, steadily collecting receivables, expanding product offerings, enhancing the team and its capabilities, and cleaning up various corporate issues such as the CUSIP, dividend, name change, audits, and other operational issues.
"The Company had a terrific third quarter and when the financial results are released investors will see that we have continued in our long term focus to collect receivables and enhance revenues, increase cash on hand while investing intelligently in the business, focus on personnel and acquiring the right business relationships, and otherwise expand the Company's role in the medical marijuana space," said Kevin Allyn, the Company's Chairman. "We are looking forward to sharing more details with our investors on each of these points in the near future. But investors will be able to measure our long term progress by how we fare against our milestones."
Previously the Company announced, that its wholly owned subsidiary Medical Greens announced that it has obtained the exclusive license for Dharmanol(TM) for the State of California. Dr. Charles Apel, of Berkeley Bio-Organic Research Laboratories has developed a proprietary technology to extract, stabilize, and preserve the medicinal cannabinoids found in hemp and marijuana in their non-psychoactive form. This technology allows patients to consume cannabinoid medicine without any of the "high" or "stoned" effects.
Dharmanol(TM) (pronounced DAR-mah-nol) will be available in two forms: low-dose non-psychoactive tablets and high-doses. The low-dose non-psychoactive tablets can be taken daily as a nutritional supplement to stimulate the endo-cannabinoid system, an internal system which controls and regulates many other bodily systems such as immune response. Much research has shown that there is substantial medicinal benefit in "stimulating" a compromised endo-cannabinoid system with cannabinoids, causing the other systems to work as they should.
The Company reserves the right to modify or amend its milestones at any time in response to business issues or for any other reason.
About SK3 Group, Inc. SK3 is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 brings standardization and transparency to this rapidly growing segment of the alternative care field.
Safe Harbor Statement Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes", "expects", "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. This news release speaks as of the date first set forth above and no responsibility or obligation may be assumed or exists to update the information included herein for events occurring after the date
FDA Disclaimer These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent disease. Use only as directed.
Edited version
SKTO Announces Third Quarter Report Date. Also Announces Conference Call and Company Milestones.
SK3 Group, Inc. (OTC Pink:SKTO) ("the Company") announced that it plans to release its Quarter III results by month's end.
"Having enhanced our operations and having bolstered our managerial services, the Company is able to report the results of its operations for Quarter III and for the 9 months ending 30 September 2013 earlier than required," said Artemus Mayor, president of SK3 Group, Inc.
"Shortly after reporting our Quarter III fiscal results, we will post on http://www.medicalgreens.com a pre-recorded conference call with the officers of the Company discussing the results and replying to investor questions," added Mr. Mayor.
According to Kevin Allyn, Chairman of SK3 Group, Inc., "The Company had a terrific third quarter."
Mr. Allyn continued, "When the financial results are released, investors will see that we continue in our long-term focus to collect receivables, enhance revenues, and increase cash on hand -- while investing intelligently in the business. We also continue to focus on personnel and acquiring the right business relationships, as we expand the Company's role in the medical marijuana space. We look forward to sharing more details with our investors on each of these points in the near future. Investors will be able to measure our long term progress by how we fare against our milestones."
For the near term, the Company's milestones include increasing revenues, steadily collecting receivables, expanding product offerings, and enhancing the team and its capabilities. Other milestones include cleaning up various corporate matters such as the Company name change, CUSIP change, dividend, audits, and other operational issues.
Previously, the Company announced that its wholly owned subsidiary Medical Greens has obtained the exclusive license for Dharmanol(TM) for the State of California. Dr. Charles Apel of Berkeley Bio-Organic Research Laboratories has developed a proprietary technology to extract, stabilize, and preserve the medicinal cannabinoids found in hemp and marijuana in their non-psychoactive form. This technology allows patients to consume cannabinoid medicine without any of the "high" or "stoned" effects.
Dharmanol(TM) (pronounced DAR-mah-nol) will be available in two forms: low-dose non-psychoactive tablets and high doses. The low-dose non-psychoactive tablets can be taken daily as a nutritional supplement to stimulate the endo-cannabinoid system, an internal system which controls and regulates many other bodily systems such as immune response. Much research has shown that there is substantial medicinal benefit in "stimulating" a compromised endo-cannabinoid system with cannabinoids, causing the other systems to work as they should.
The Company reserves the right to modify or amend its milestones at any time in response to business issues or for any other reason.
About SK3 Group, Inc. SK3 is a healthcare logistics and fulfillmentconsultancy focused on the delivery of alternative care and medicine.With seasoned management, breakthrough technology and best practices,SK3 brings standardization and transparency to this rapidly growingsegment of the alternative care field.
